We thank Dr Efthymiou for his letter [1] regarding our recent article [2] and for increasing the dialogue on what we consider an interesting, yet controversial, topic. We agree wholeheartedly with Dr Efthymiou, that submissions should be accepted on scientific merit alone and not be biased by an author's sex, gender, race, ethnicity, institution or any
other factors for that matter . He argues that 'a publication has been accepted for its scientific merit. . . in a fair and transparent process' and that he, as a reviewer himself, has been blinded to the name and sex of the author.
Unfortunately this type of double-blind review (where both author and reviewer identities are concealed) is practically very difficult and may cause more problems than it solves.
Although a full discussion is beyond the scope of this letter [3] , it is likely that a reviewer, being an expert in their field, will be able to identify a well-known author from the nature of their work, style of writing or particular research technique, even when every effort has been made to anonymise the submission. Conversely, if the author is not well known then there is no need to conceal their identity. In the double-blind review process there is no requirement for the reviewer to disclose any conflicts of interest and therefore to identify possible bias and, when the authors are deduced from a manuscript's content, the double-blind review effectively becomes a single blind review, which is what is practised in our journal. This at least allows the reviewer to recluse themselves if they do have any conflicts and may also identify author self-plagiarism.
In a recent publication, Murray et al. considered the peer review outcomes of more than 30,000 submissions to the biosciences journal eLife [4] . They found that gatekeepers (i.e. the reviewers) favoured manuscripts from authors of the same sex and same country, and that sex inequity was greatest when teams of reviewers were all men. Although the influences on success rates are multiple and complex, including not only the process of peer review but also differing submissions rates, it appears that the sex of a reviewer regrettably plays a part.
Publication metrics are still considered by many institutions as markers of scientific success, and in the medical world, where women are underrepresented at all levels, especially in senior positions, any potential for mitigating these inequities is important and should be highlighted. We agree with Dr Efthymiou that striving to achieve sex balance of journal editors is key, alongside increasing female representation among reviewers and raising awareness of possible bias that occurs, often unknowingly, in publishing. 
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